The use of albumin in all patients with decompensated cirrhosis is not justified

Israel Medical Association Journal

Volumn 7, Issue 2, 2005, Pages 118-120

  Avidan, Benjamin ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Albumin; Ascites; Cirrhosis; Hepatorenal syndrome; Spontaneous bacterial peritonitis

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; DEXTRAN 70; DIURETIC AGENT; LOOP DIURETIC AGENT; PLASMA SUBSTITUTE; POLYGELINE;

ASCITES; ASCITES FLUID; BACTERIAL PERITONITIS; CIRCULATION; CLINICAL TRIAL; DRUG FATALITY; DRUG USE; HEPATORENAL SYNDROME; HUMAN; HYPOALBUMINEMIA; HYPOVOLEMIA; LIVER CIRRHOSIS; MEDICAL DECISION MAKING; NOTE; PARACENTESIS; TREATMENT PLANNING;

ASCITES; DIURETICS; HEPATORENAL SYNDROME; HUMANS; HYPOALBUMINEMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PERITONITIS; SERUM ALBUMIN;

EID: 13844320529     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (23)

1. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
2. Llach J, Gines P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to hospital for the treatment of ascites. Gastroenterology 1988;99:482-7.
3. Quintero E, Gines P, Arroyo V, et al. Paracentesis versus diuretics in the treatment of cirrhosis with tense ascites. Lancet 1985;1:611-12.
4. Runyon BA. Management of adult paients with ascites caused by cirrhosis. Hepatology 1988;27:264-72.
5. Vermeulen LC, Ratko TA, Erstad BL. The university hospital consortium guidelines for the use of albumin, non-protein colloids, and crystalloid solutions. Arch Intern Med 1995;155:373-9.
6. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomized controlled trials. Br Med J 1998;317:235-40.
7. Drummond G. Albumin and the Medicines Control Agency. Br Med J 1999;354:1038.
8. Horsey P. Albumin and hypoalbuminemia: is the Cochrane evidence to be trusted? Lancet 2002;359:70-2.
9. Gentilini P, La Villa G, Marra F, et al. Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites. Hepatology 1996;25:481-90.
10. Gentilini P, Cassini-Raggi V, DiFiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized controlled trial. J Hepatol 1999;30:639-45.
11. Arroyo V, Sort P, Gins P, et al. Treatment of ascites by paracentesis. In; Arroyo V, Gines P, Rhodes J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. Oxford: Blackwell Science, 1999:463-79.
12. Gines P, Arroyo V, Planas R, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493-502.
13. Gines P, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;11:1002-10.
14. Peltekian KM, Wong F, Liu PP, et al. Cardiovascular, renal, and neurohumoral responses to single volume paracentesis in patients with cirrhosis and diuretic resistant ascites. Am J Gastroenterol 1997;92:394-9.
15. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-501.
16. Navasa M, Follow A, Fillela X. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998;27: 1227-32.
17. Toledo C, Salmeron JM, Rimola A, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993;17:251-7.
18. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9.
19. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodine and octreotide. Hepatology 1999;29:1690-7.
20. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged admission of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41.
21. Gilberg V, Bilzer M, Gerbe AL. Long term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and albumin. Hepatology 1999; 30: 870-5.
22. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin in patients with hepatorenal syndrome: results of a prospective, non-randomized trial. Hepatology 2002;36:941-8.
23. Devoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-80.